Clinical impact of early brain atrophy in clinically isolated syndromes
Background: The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not fully gauged. Objectives: We aimed to determine the magnitude and clinical relevance of brain volume dynamics in the first year after a CIS. M...
Gespeichert in:
| Veröffentlicht in: | Multiple sclerosis 2013-12, Vol.19 (14), p.1878-1886 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1886 |
|---|---|
| container_issue | 14 |
| container_start_page | 1878 |
| container_title | Multiple sclerosis |
| container_volume | 19 |
| creator | Pérez-Miralles, F Sastre-Garriga, J Tintoré, M Arrambide, G Nos, C Perkal, H Río, J Edo, MC Horga, A Castilló, J Auger, C Huerga, E Rovira, A Montalban, X |
| description | Background:
The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not fully gauged.
Objectives:
We aimed to determine the magnitude and clinical relevance of brain volume dynamics in the first year after a CIS.
Methods:
We assessed 176 patients with CIS within 3 months of onset, clinically and by conventional magnetic resonance imaging (MRI) scans, at baseline and 1 year after clinical onset. We determined the percentage of brain volume change (PBVC) and the brain parenchymal (BPF), grey matter (GMF) and white matter (WMF) fractions.
Results:
The mean follow-up time was 53 months (SD = 16.8): 76 patients (43%) experienced a second attack, 32 (18%) fulfilled MRI-only 2005 McDonald criteria and 68 (39%) remained as CIS. Statistically significant decreases in the volume measures tested were observed in patients with a second attack, for BPF and PBVC; in both MS groups for GMF; whereas in all groups, the WMF was unchanged. Patients with a second attack had larger PBVC decreases (− 0.65% versus + 0.059%; p < 0.001). PBVC decreases below − 0.817% independently predicted shorter times to a second attack.
Conclusions:
Global brain and grey matter volume loss occurred within the first year after a CIS; brain volume loss predicted conversion to MS. |
| doi_str_mv | 10.1177/1352458513488231 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1462187850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1352458513488231</sage_id><sourcerecordid>3143645801</sourcerecordid><originalsourceid>FETCH-LOGICAL-c395t-f408484b22ef8540d1571e61d06174c5a659724b5a15a7e2f9a9abc92d8427353</originalsourceid><addsrcrecordid>eNp1kM1LxDAQxYMorq7ePUlBBC_VJM00yVEWXYUFL3ou0zTVLv0yaQ_9782y6wcLnmbg_ebN4xFywegtY1LesQS4AAUsEUrxhB2QEyakjKmW9DDsQY43-oycer-mlEqZwDGZ8SQFzhmckOWirtrKYB1VTY9miLoysujqKcodVm2Eg-v6jykKq9mRQat8V-Ngi8hPbeG6xvozclRi7e35bs7J2-PD6-IpXr0snxf3q9gkGoa4FFQJJXLObalA0IKBZDZlBU2ZFAYwBS25yAEZoLS81KgxN5oXSvCQPZmTm61v77rP0fohaypvbF1ja7vRZ0yknCmpgAb0ag9dd6NrQ7oNlYBWADJQdEsZ13nvbJn1rmrQTRmj2abkbL_kcHK5Mx7zxhY_B9-tBuB6B6APhZUOW1P5X05qraTYGMVbzuO7_ZPuv8df9rqOfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1463598557</pqid></control><display><type>article</type><title>Clinical impact of early brain atrophy in clinically isolated syndromes</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Pérez-Miralles, F ; Sastre-Garriga, J ; Tintoré, M ; Arrambide, G ; Nos, C ; Perkal, H ; Río, J ; Edo, MC ; Horga, A ; Castilló, J ; Auger, C ; Huerga, E ; Rovira, A ; Montalban, X</creator><creatorcontrib>Pérez-Miralles, F ; Sastre-Garriga, J ; Tintoré, M ; Arrambide, G ; Nos, C ; Perkal, H ; Río, J ; Edo, MC ; Horga, A ; Castilló, J ; Auger, C ; Huerga, E ; Rovira, A ; Montalban, X</creatorcontrib><description>Background:
The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not fully gauged.
Objectives:
We aimed to determine the magnitude and clinical relevance of brain volume dynamics in the first year after a CIS.
Methods:
We assessed 176 patients with CIS within 3 months of onset, clinically and by conventional magnetic resonance imaging (MRI) scans, at baseline and 1 year after clinical onset. We determined the percentage of brain volume change (PBVC) and the brain parenchymal (BPF), grey matter (GMF) and white matter (WMF) fractions.
Results:
The mean follow-up time was 53 months (SD = 16.8): 76 patients (43%) experienced a second attack, 32 (18%) fulfilled MRI-only 2005 McDonald criteria and 68 (39%) remained as CIS. Statistically significant decreases in the volume measures tested were observed in patients with a second attack, for BPF and PBVC; in both MS groups for GMF; whereas in all groups, the WMF was unchanged. Patients with a second attack had larger PBVC decreases (− 0.65% versus + 0.059%; p < 0.001). PBVC decreases below − 0.817% independently predicted shorter times to a second attack.
Conclusions:
Global brain and grey matter volume loss occurred within the first year after a CIS; brain volume loss predicted conversion to MS.</description><identifier>ISSN: 1352-4585</identifier><identifier>EISSN: 1477-0970</identifier><identifier>DOI: 10.1177/1352458513488231</identifier><identifier>PMID: 23652215</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adrenal Cortex Hormones - therapeutic use ; Adult ; Atrophy ; Biological and medical sciences ; Brain - drug effects ; Brain - pathology ; Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases ; Demyelinating Diseases - drug therapy ; Demyelinating Diseases - pathology ; Disability Evaluation ; Disease Progression ; Female ; Humans ; Immunologic Factors - therapeutic use ; Injuries of the nervous system and the skull. Diseases due to physical agents ; Longitudinal Studies ; Magnetic Resonance Imaging ; Male ; Medical sciences ; Multiple Sclerosis - drug therapy ; Multiple Sclerosis - pathology ; Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis ; Neurology ; Organ Size ; Prospective Studies ; Recurrence ; Time Factors ; Traumas. Diseases due to physical agents ; Young Adult</subject><ispartof>Multiple sclerosis, 2013-12, Vol.19 (14), p.1878-1886</ispartof><rights>The Author(s) 2013</rights><rights>2015 INIST-CNRS</rights><rights>SAGE Publications © Dec 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c395t-f408484b22ef8540d1571e61d06174c5a659724b5a15a7e2f9a9abc92d8427353</citedby><cites>FETCH-LOGICAL-c395t-f408484b22ef8540d1571e61d06174c5a659724b5a15a7e2f9a9abc92d8427353</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1352458513488231$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1352458513488231$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27998741$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23652215$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pérez-Miralles, F</creatorcontrib><creatorcontrib>Sastre-Garriga, J</creatorcontrib><creatorcontrib>Tintoré, M</creatorcontrib><creatorcontrib>Arrambide, G</creatorcontrib><creatorcontrib>Nos, C</creatorcontrib><creatorcontrib>Perkal, H</creatorcontrib><creatorcontrib>Río, J</creatorcontrib><creatorcontrib>Edo, MC</creatorcontrib><creatorcontrib>Horga, A</creatorcontrib><creatorcontrib>Castilló, J</creatorcontrib><creatorcontrib>Auger, C</creatorcontrib><creatorcontrib>Huerga, E</creatorcontrib><creatorcontrib>Rovira, A</creatorcontrib><creatorcontrib>Montalban, X</creatorcontrib><title>Clinical impact of early brain atrophy in clinically isolated syndromes</title><title>Multiple sclerosis</title><addtitle>Mult Scler</addtitle><description>Background:
The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not fully gauged.
Objectives:
We aimed to determine the magnitude and clinical relevance of brain volume dynamics in the first year after a CIS.
Methods:
We assessed 176 patients with CIS within 3 months of onset, clinically and by conventional magnetic resonance imaging (MRI) scans, at baseline and 1 year after clinical onset. We determined the percentage of brain volume change (PBVC) and the brain parenchymal (BPF), grey matter (GMF) and white matter (WMF) fractions.
Results:
The mean follow-up time was 53 months (SD = 16.8): 76 patients (43%) experienced a second attack, 32 (18%) fulfilled MRI-only 2005 McDonald criteria and 68 (39%) remained as CIS. Statistically significant decreases in the volume measures tested were observed in patients with a second attack, for BPF and PBVC; in both MS groups for GMF; whereas in all groups, the WMF was unchanged. Patients with a second attack had larger PBVC decreases (− 0.65% versus + 0.059%; p < 0.001). PBVC decreases below − 0.817% independently predicted shorter times to a second attack.
Conclusions:
Global brain and grey matter volume loss occurred within the first year after a CIS; brain volume loss predicted conversion to MS.</description><subject>Adrenal Cortex Hormones - therapeutic use</subject><subject>Adult</subject><subject>Atrophy</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - pathology</subject><subject>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</subject><subject>Demyelinating Diseases - drug therapy</subject><subject>Demyelinating Diseases - pathology</subject><subject>Disability Evaluation</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humans</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Injuries of the nervous system and the skull. Diseases due to physical agents</subject><subject>Longitudinal Studies</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Multiple Sclerosis - drug therapy</subject><subject>Multiple Sclerosis - pathology</subject><subject>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</subject><subject>Neurology</subject><subject>Organ Size</subject><subject>Prospective Studies</subject><subject>Recurrence</subject><subject>Time Factors</subject><subject>Traumas. Diseases due to physical agents</subject><subject>Young Adult</subject><issn>1352-4585</issn><issn>1477-0970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kM1LxDAQxYMorq7ePUlBBC_VJM00yVEWXYUFL3ou0zTVLv0yaQ_9782y6wcLnmbg_ebN4xFywegtY1LesQS4AAUsEUrxhB2QEyakjKmW9DDsQY43-oycer-mlEqZwDGZ8SQFzhmckOWirtrKYB1VTY9miLoysujqKcodVm2Eg-v6jykKq9mRQat8V-Ngi8hPbeG6xvozclRi7e35bs7J2-PD6-IpXr0snxf3q9gkGoa4FFQJJXLObalA0IKBZDZlBU2ZFAYwBS25yAEZoLS81KgxN5oXSvCQPZmTm61v77rP0fohaypvbF1ja7vRZ0yknCmpgAb0ag9dd6NrQ7oNlYBWADJQdEsZ13nvbJn1rmrQTRmj2abkbL_kcHK5Mx7zxhY_B9-tBuB6B6APhZUOW1P5X05qraTYGMVbzuO7_ZPuv8df9rqOfg</recordid><startdate>20131201</startdate><enddate>20131201</enddate><creator>Pérez-Miralles, F</creator><creator>Sastre-Garriga, J</creator><creator>Tintoré, M</creator><creator>Arrambide, G</creator><creator>Nos, C</creator><creator>Perkal, H</creator><creator>Río, J</creator><creator>Edo, MC</creator><creator>Horga, A</creator><creator>Castilló, J</creator><creator>Auger, C</creator><creator>Huerga, E</creator><creator>Rovira, A</creator><creator>Montalban, X</creator><general>SAGE Publications</general><general>Sage Publications</general><general>Sage Publications Ltd</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TK</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9-</scope><scope>K9.</scope><scope>M0R</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20131201</creationdate><title>Clinical impact of early brain atrophy in clinically isolated syndromes</title><author>Pérez-Miralles, F ; Sastre-Garriga, J ; Tintoré, M ; Arrambide, G ; Nos, C ; Perkal, H ; Río, J ; Edo, MC ; Horga, A ; Castilló, J ; Auger, C ; Huerga, E ; Rovira, A ; Montalban, X</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c395t-f408484b22ef8540d1571e61d06174c5a659724b5a15a7e2f9a9abc92d8427353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adrenal Cortex Hormones - therapeutic use</topic><topic>Adult</topic><topic>Atrophy</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - pathology</topic><topic>Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases</topic><topic>Demyelinating Diseases - drug therapy</topic><topic>Demyelinating Diseases - pathology</topic><topic>Disability Evaluation</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humans</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Injuries of the nervous system and the skull. Diseases due to physical agents</topic><topic>Longitudinal Studies</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Multiple Sclerosis - drug therapy</topic><topic>Multiple Sclerosis - pathology</topic><topic>Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis</topic><topic>Neurology</topic><topic>Organ Size</topic><topic>Prospective Studies</topic><topic>Recurrence</topic><topic>Time Factors</topic><topic>Traumas. Diseases due to physical agents</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pérez-Miralles, F</creatorcontrib><creatorcontrib>Sastre-Garriga, J</creatorcontrib><creatorcontrib>Tintoré, M</creatorcontrib><creatorcontrib>Arrambide, G</creatorcontrib><creatorcontrib>Nos, C</creatorcontrib><creatorcontrib>Perkal, H</creatorcontrib><creatorcontrib>Río, J</creatorcontrib><creatorcontrib>Edo, MC</creatorcontrib><creatorcontrib>Horga, A</creatorcontrib><creatorcontrib>Castilló, J</creatorcontrib><creatorcontrib>Auger, C</creatorcontrib><creatorcontrib>Huerga, E</creatorcontrib><creatorcontrib>Rovira, A</creatorcontrib><creatorcontrib>Montalban, X</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Multiple sclerosis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pérez-Miralles, F</au><au>Sastre-Garriga, J</au><au>Tintoré, M</au><au>Arrambide, G</au><au>Nos, C</au><au>Perkal, H</au><au>Río, J</au><au>Edo, MC</au><au>Horga, A</au><au>Castilló, J</au><au>Auger, C</au><au>Huerga, E</au><au>Rovira, A</au><au>Montalban, X</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical impact of early brain atrophy in clinically isolated syndromes</atitle><jtitle>Multiple sclerosis</jtitle><addtitle>Mult Scler</addtitle><date>2013-12-01</date><risdate>2013</risdate><volume>19</volume><issue>14</issue><spage>1878</spage><epage>1886</epage><pages>1878-1886</pages><issn>1352-4585</issn><eissn>1477-0970</eissn><abstract>Background:
The impact of global and tissue-specific brain atrophy on conversion to multiple sclerosis (MS) after a clinically isolated syndrome (CIS) is not fully gauged.
Objectives:
We aimed to determine the magnitude and clinical relevance of brain volume dynamics in the first year after a CIS.
Methods:
We assessed 176 patients with CIS within 3 months of onset, clinically and by conventional magnetic resonance imaging (MRI) scans, at baseline and 1 year after clinical onset. We determined the percentage of brain volume change (PBVC) and the brain parenchymal (BPF), grey matter (GMF) and white matter (WMF) fractions.
Results:
The mean follow-up time was 53 months (SD = 16.8): 76 patients (43%) experienced a second attack, 32 (18%) fulfilled MRI-only 2005 McDonald criteria and 68 (39%) remained as CIS. Statistically significant decreases in the volume measures tested were observed in patients with a second attack, for BPF and PBVC; in both MS groups for GMF; whereas in all groups, the WMF was unchanged. Patients with a second attack had larger PBVC decreases (− 0.65% versus + 0.059%; p < 0.001). PBVC decreases below − 0.817% independently predicted shorter times to a second attack.
Conclusions:
Global brain and grey matter volume loss occurred within the first year after a CIS; brain volume loss predicted conversion to MS.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>23652215</pmid><doi>10.1177/1352458513488231</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1352-4585 |
| ispartof | Multiple sclerosis, 2013-12, Vol.19 (14), p.1878-1886 |
| issn | 1352-4585 1477-0970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1462187850 |
| source | MEDLINE; SAGE Complete |
| subjects | Adrenal Cortex Hormones - therapeutic use Adult Atrophy Biological and medical sciences Brain - drug effects Brain - pathology Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Demyelinating Diseases - drug therapy Demyelinating Diseases - pathology Disability Evaluation Disease Progression Female Humans Immunologic Factors - therapeutic use Injuries of the nervous system and the skull. Diseases due to physical agents Longitudinal Studies Magnetic Resonance Imaging Male Medical sciences Multiple Sclerosis - drug therapy Multiple Sclerosis - pathology Multiple sclerosis and variants. Guillain barré syndrome and other inflammatory polyneuropathies. Leukoencephalitis Neurology Organ Size Prospective Studies Recurrence Time Factors Traumas. Diseases due to physical agents Young Adult |
| title | Clinical impact of early brain atrophy in clinically isolated syndromes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T16%3A38%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20impact%20of%20early%20brain%20atrophy%20in%20clinically%20isolated%20syndromes&rft.jtitle=Multiple%20sclerosis&rft.au=P%C3%A9rez-Miralles,%20F&rft.date=2013-12-01&rft.volume=19&rft.issue=14&rft.spage=1878&rft.epage=1886&rft.pages=1878-1886&rft.issn=1352-4585&rft.eissn=1477-0970&rft_id=info:doi/10.1177/1352458513488231&rft_dat=%3Cproquest_cross%3E3143645801%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1463598557&rft_id=info:pmid/23652215&rft_sage_id=10.1177_1352458513488231&rfr_iscdi=true |